Regeneron’s bispecific lymphoma antibody odronextamab wins FDA priority review
The FDA has set 31 March 2024 as the PDUFA action date for reviewing odronextamab as third-line therapy for FL and DLBCL.
ModeX wins $168m BARDA contract to develop viral antibody therapies
Can reforms restore faith in India’s pharma industry after cough syrup scandals?
AI is a pillar of tomorrow’s healthcare system, but limitations remain
Amicus receives FDA approval for Pompe disease therapy
HitGen and SGC enter drug discovery partnership
Analysis
View More
Themes
View MoreGenerative AI-focused biotech startup Evozyne raises $81m
The company’s algorithms put proteins through millions of years of simulated evolution to identify potential functional candidates.
More themes
Premium Insights
View MoreLeading innovators with viral vectors for the pharmaceutical industry
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Discover premium insights powered by our properietary data
Understand the themes driving your sector, keep up with key innovation areas and track the activities of leading companies
More Insights
Buyer's Guides
View More
ADDF invest in BrainScope for Alzheimer’s prediction biomarker
Market cap rebound by top 20 biopharmaceutical companies in Q2 2023
EMA CHMP recommends approval for Moderna’s updated Covid-19 vaccine
Corporate sustainability needs ESG standards and tools